Virginia K Clements
Overview
Explore the profile of Virginia K Clements including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
3755
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Clements V, Long T, Long R, Figley C, Smith D, Ostrand-Rosenberg S
J Leukoc Biol
. 2018 Jan;
103(3):395-407.
PMID: 29345342
Obesity is a risk factor for cancer incidence and cancer mortality. The association of obesity and cancer is attributed to multiple factors, but the tightest linkage is with the chronic,...
2.
Geis-Asteggiante L, Belew A, Clements V, Edwards N, Ostrand-Rosenberg S, El-Sayed N, et al.
J Proteome Res
. 2017 Nov;
17(1):486-498.
PMID: 29139296
Myeloid-derived suppressor cells (MDSC) are immature myeloid cells that accumulate in the circulation and the tumor microenvironment of most cancer patients. There, MDSC suppress both adaptive and innate immunity, hindering...
3.
Adams K, Chauhan S, Patel D, Clements V, Wang Y, Jay S, et al.
J Proteome Res
. 2017 Oct;
17(1):315-324.
PMID: 29061044
Ubiquitinated proteins carried by the extracellular vesicles (EV) released by myeloid-derived suppressor cells (MDSC) have been investigated using proteomic strategies to examine the effect of tumor-associated inflammation. EV were collected...
4.
Horn L, Ciavattone N, Atkinson R, Woldergerima N, Wolf J, Clements V, et al.
Oncotarget
. 2017 Sep;
8(35):57964-57980.
PMID: 28938530
Bi-specific T cell engagers (BiTEs) activate T cells through CD3 and target activated T cells to tumor-expressed antigens. BiTEs have shown therapeutic efficacy in patients with liquid tumors; however, they...
5.
Ostrand-Rosenberg S, Sinha P, Figley C, Long R, Park D, Carter D, et al.
J Leukoc Biol
. 2016 Dec;
101(5):1091-1101.
PMID: 28007981
During successful pregnancy, a woman is immunologically tolerant of her genetically and antigenically disparate fetus, a state known as maternal-fetal tolerance. How this state is maintained has puzzled investigators for...
6.
Ku A, Muhitch J, Powers C, Diehl M, Kim M, Fisher D, et al.
Elife
. 2016 Dec;
5.
PMID: 27929373
Myeloid-derived suppressor cells (MDSC) contribute to an immunosuppressive network that drives cancer escape by disabling T cell adaptive immunity. The prevailing view is that MDSC-mediated immunosuppression is restricted to tissues...
7.
Parker K, Sinha P, Horn L, Clements V, Yang H, Li J, et al.
Cancer Res
. 2014 Aug;
74(20):5723-33.
PMID: 25164013
Chronic inflammation often precedes malignant transformation and later drives tumor progression. Likewise, subversion of the immune system plays a role in tumor progression, with tumoral immune escape now well recognized...
8.
Ostrand-Rosenberg S, Sinha P, Beury D, Clements V
Semin Cancer Biol
. 2012 Feb;
22(4):275-81.
PMID: 22313874
The tumor microenvironment is a complex milieu of tumor and host cells. Host cells can include tumor-reactive T cells capable of killing tumor cells. However, more frequently the tumor and...
9.
Sinha P, Chornoguz O, Clements V, Artemenko K, Zubarev R, Ostrand-Rosenberg S
Blood
. 2011 Apr;
117(20):5381-90.
PMID: 21450901
Myeloid-derived suppressor cells (MDSCs) inhibit adaptive and innate immunity and accumulate in the blood of persons with cancer, chronic inflammation, trauma, infection, and stress. Some of the factors inducing their...
10.
Srivastava M, Sinha P, Clements V, Rodriguez P, Ostrand-Rosenberg S
Cancer Res
. 2009 Dec;
70(1):68-77.
PMID: 20028852
Myeloid-derived suppressor cells (MDSC) are present in most cancer patients and are potent inhibitors of T-cell-mediated antitumor immunity. Their inhibitory activity is attributed to production of arginase, reactive oxygen species,...